BioAge Labs Inc
BioAge Labs Inc (BIOA) Covered Calls
BioAge Labs Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 100.00%, high versus the past year. BIOA's highest covered call setup is the $15.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 170.27% out of the money with 35 days to expiration, a 171.17% return until expiration, and a 1,785.07% theoretical annualized return. Across the setups shown, annualized returns run from 196.44% to 1,785.07% at strikes between $7.50 and $15.00, with 35 to 154 days to expiration, as of Nov 13, 2026.
Read more
Running BIOA covered calls helps you generate income from BioAge Labs Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BIOA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If BIOA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BIOA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BIOA covered call is worth writing.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation.
| 2026-12-18 | 35 | 15.00 | 170.27 | 0.05 | 2.85 | 950.00 | 171.17 | 1785.07 | -0.90 | +0.48 | 3 | 2.80 |
| 2027-01-15 | 63 | 10.00 | 80.18 | 0.15 | 0.75 | 460.00 | 82.88 | 480.19 | -2.70 | +0.28 | 1,040 | 0.60 |
| 2026-12-18 | 35 | 7.50 | 35.14 | 0.05 | 0.40 | 200.00 | 36.04 | 375.80 | -0.90 | +0.24 | 16 | 0.35 |
| 2027-04-16 | 154 | 10.00 | 80.18 | 0.15 | 3.50 | 460.00 | 82.88 | 196.44 | -2.70 | +0.57 | 0 | 3.35 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - Specialty & Generic
- SectorHealthcare
- IV Rank100.00% High
- Market cap (M$)255
- 52 weeks high-78.62%
- 52 weeks low15.38%
- Analyst recommendationBuy
1.60 - Target price$28.56
414.59% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-2.55
- EPS growth next 5 years-4.97%
As of Nov 13, 2026